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Purpose: Complementary and Alternative Medicine (CAM) interventions are widely used
by patients with chronic disorders, including cancer, and may interact with cancer
treatment. Physicians are often unaware of this, probably due to poor patient-physician
communication on CAM. The purpose of this study was to evaluate physicians’
knowledge, attitudes and practice patterns regarding CAM in a survey conducted in Italy.
Methods: A questionnaire was administered to 438 physicians (11 Italian hospitals) who
predominantly treat patients with chronic disease, to collect personal and professional
data and information on attitudes toward CAM and its possible role in Conventional
Medicine (CM).
Results: Of the 438 participants, most were specialists in oncology (18%),
internal medicine (17%), surgery (15%), and radiotherapy (11%). Most worked
at university (44%) or research hospitals (31%). Forty-two percent of participants
believed that CAM could have an integrative role within CM. Oncologists were
the physicians who were best informed on CAM (58%). Physicians working
at research institutes or university hospitals had a greater knowledge of CAM
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than those employed at general hospitals (p < 0.0001), and those who were also
involved in research activity had a greater knowledge of CAM than those who were not
(p < 0.003). Length of work experience was significantly related to CAM knowledge.
Moreover, 55% of participants suggest CAM interventions to their patients and 44%
discuss CAM with them. The best-known interventions were acupuncture, Aloe vera and
high-dose vitamin C.
Conclusion: CAM use by patients with chronic disease and/or cancer has become a
topical issue for the scientific community and for physicians. Knowing the reasons that
prompt these patients to use CAM and guiding them in their decisions would improve
treatment and outcomes and also benefit healthcare systems. Our findings contribute
to a greater understanding of CAM knowledge, attitudes, and practice among Italian
physicians. Further research is needed to identify the more effective CAM treatments
and to work toward an integrated healthcare model.
Keywords: complementary medicine, alternative medicine, physicians, cancer, treatment, Italian survey, attitudes
INTRODUCTION
According to the U.S. National Center for Complementary and
Integrative Health (NCCIH), Complementary and Alternative
Medicine (CAM) therapies include a wide spectrum of practices
and products, either biological (e.g., herbs or botanicals,
vitamins, minerals, probiotics, homeopathic products, and
Chinese herbal remedies) or non-biological (e.g., prayer,
meditation, music therapy, yoga). These interventions
are defined as “alternative” when they are used instead of
Conventional Medicine (CM) and as “complementary” when
they are used together with it (1). Their popularity has been
increasing, and according to 26 studies conducted all over
the world by the 1990s they were used by 7–64% of patients
with chronic disorders, including cancer (2–5). In the past
decade the interest in CAM has grown further, the main reasons
being massive internet marketing, dissatisfaction with CM, and
a desire by patients to achieve greater control over medical
decisions (2).
CAM has become widespread in most industrialized
countries; individuals who have used it at least once account
for about 70% of the population in Canada (6), ∼50% in Italy,
France and Australia (7–9), 40% in the USA (3), 30% in Japan
(2), and 31% in Belgium (8).
The diffusion of CAM therapies is relevant to physicians,
because several biologically based approaches, such as herbs and
supplements, can interfere with CM treatment efficacy, including
antiblastic chemotherapy (AC) and target therapy (TT), besides
heightening the risk of treatment-related toxicity and other
complications. For example, St John’s wort, Asian ginseng and
green tea have all been found to induce toxicity and to interact
with a number of medications, including AC and TT (10–13). A
study of adult cancer patients estimated that 28% were at risk of
AC-herb interactions; notably, 46% of these patients were treated
with curative intent (14). The interactions described between
the most common AC and CAM interventions published in the
English literature are reported in Table 1 (15–42). To the best of
our knowledge, there are no studies in English on interactions
between immunotherapy and CAM.
The wide diffusion of CAM and the attendant risk for some
patients—especially those receiving active anticancer treatment
(ACT)—involve that physicians should inquire about their use by
patients and be familiar with the more common CAM therapies.
In a recent multicentre Italian study (7), we found that
49% of cancer patients combined CAM remedies with their
ACT and that in 67% of cases the interventions were self-
prescribed. Their main sources of information were the internet
and the media (48%), whereas only 6% of patients received
information on CAM from physicians. Critically, 85% of patients
were not aware of the risk of side-effects of CAM remedies
and of potential interactions with CM treatments. The latter
issue raises disturbing questions and highlights the need for
greater patient-physician communication on CAM. Although
oncologists generally discuss treatment options with patients
(choice of treatment, therapeutic targets, side-effects), they
largely ignore CAM (43–45). A study conducted at the University
of Texas MD Anderson Cancer Center in Houston has found
limited communication and discordant views among physicians
with regard to CAM therapies (46). Insufficient patient-
oncologist communication on CAM has also been reported
(46). Poor communication between healthcare professionals
and patients has been described with regard to CAM; for
instance, in a previous Italian multicentre survey, Crocetti et al.
(47) highlighted a poor attitude of oncologists toward CAM.
According to data published by Censis (an Italian socioeconomic
research body) on fake news on medications in 2017, 28% of
Italians who have a medical problem consult primarily “Dr
Google,” likely due to poor or no communication with their
physicians (48).
The medical education of Italian physicians is evidence-based.
Most have never been taught CAM at any stage of their training, a
fact that may be ascribed to lack of significant scientific evidence
for its effectiveness. Indeed, the current literature on CAM and
cancer is largely based on the patients’ standpoint, whereas papers
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TABLE 1 | Most common CAM interventions adopted by cancer patients and possible interactions with AC.
CAM agents Metabolic pathway Interaction with cancer
treatments
Adverse events Reference
Active hexose-correlated compound
isolated from shiitake mushrooms
CYP2D6 induction May reduce the activity of ADM,
which is a substrate of this enzyme,
and of AIs
Diarrhea and itching (15)
Ananas Pineapple (bromelain) CYP2C9 inhibition Risk of overdosage in patients
treated with TXL
Exacerbation of hand and foot
syndrome
(16)
β-carotene Alcohol consumption has an
adverse effect on β-carotene activity
The hepatotoxic effects of ethanol
may be potentiated by high-dose
β-carotene
(17)
B-elemene (terpene from Rhizoma
zedoariae and mint)
Increased DDP and taxane activity No adverse events recorded (18)
Bitter melon (Momordica charantia) P-gp and CYP2C9 inhibition Increased intracellular concentration
VBL and TXL
No adverse events were recorded (19)
Turmeric (Curcuma longa) Weak CYP1A2, CYP2B6, CYP2C9,
and CYP2D6 inhibition
Risk of overdosage in patients
treated with bendamustine and
inefficacy of prodrugs (CTX, TAM)
Allergic dermatitis and bile duct
obstruction
(20)
Cannabinoids CYP2C9 induction Risk of overdosage in patients
treated with prodrugs (CTX, TAM)
Gastrointestinal complaints∧ (21)
Di Bella multitherapy§ GH inhibition, enhances IGF-binding
protein-1 secretion
The opioid antagonist properties of
somatostatin reduce the analgesic
effect of opioids in patients with
advanced cancer
Gastrointestinal complaints∧,
cholelithiasis, and hyperglycaemia
(22)
Echinacea Potent CYP3A4 inhibition Improved pharmacokinetics of CTX,
DAS, TXT, ERL, IMT, SOR (weak)
VALK (high), and VP16
Severe thrombocytopaenia in a
patient receiving VP16
(23)
Essiac* CYP3A4 inhibition Risk of overdosage in patients
treated with BTZ, DAS, TXT, ERL,
IMT, SOR, VALK
Gastrointestinal complaints∧ (24)
Folic acid MTHFR-enhancing activity Improved activity of antimetabolite
drugs (5-Fu)
Concurrent use of folic acid may
antagonize the effects of certain
anticonvulsants
(25)
Glucans from mushrooms◦ EGFr and mTOR inhibition May antagonize TAM in patients
with estrogen-positive breast
cancer
Immunosuppressive effects (26)
Green tea CYP3A4 inhibition Similar to Essiac High ALT levels (27)
Gingko biloba CYP3A4 CYP2C19, P-gp Similar to Essiac Nervousness (28)
Ginseng CYP3A4 inhibition Increased risk of IMT hepatotoxicity High ALT levels (29)
Glutathione GSH, GSTP1 Increased AC detoxification Mucosal hypersecretion (30)
Grapefruit (including juice) CYP3A4 inhibition Not recommended during ADM due
to oxidations
Gastrointestinal complaints∧ (31)
Liquorice weak CYP2B6, CYP3A4 inhibition Similar to Essiac (weak) Hypertension, retinopathy and
nephropathy
(32)
Milk thistle Weak CYP2C8 and CYP2C9
inhibition
Risk of overdosage in patients
taking CTX, TXL
No adverse events recorded (33)
Oleander P-gp and mTOR inhibition May increase the blood levels of
substrate drugs such as TKIs.
Gastrointestinal complaints∧ (34)
Omega 3 p53 Reduces platin activity Platin-drug resistance (35)
Ozone therapy ND Not recommended during ADM due
to oxidation
ND (36)
Quercetin Strong CYP3A4 and CYP2C19
inhibition
Similar to Essiac High ALT levels (37)
Resveratrol CYP3A4, CYP2D6, CYP2C9,
inhibition
Protective effects against DDP- and
ADM-induced cardiotoxicity, due to
upregulation of SIRT1-mediated
p53 deacetylation
No adverse events recorded (38)
Spirulina and blue-green algae CYP 1A2 and 2E1 inhibitions Induces accumulation of drugs
metabolized by these enzymes,
including bendamustine
Increases the risk of their side
effects
(39)
(Continued)
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TABLE 1 | Continued
CAM agents Metabolic pathway Interaction with cancer
treatments
Adverse events Reference
St. John’s worth (Hypericum) CYP3A4 induction Improved CTX, DAS, TXT, ERL, IMT,
SOR, and VALK pharmacokinetics
Headache, dry mouth, sleepiness,
gastrointestinal complaints∧
(40)
Vitamin C ND May reduce the effectiveness of
VCR, ADM, MTX, DDP, BTZ, IMT
Kidney stones (41)
Zeolite Protein kinase B inhibition Enhances the effect of ADM due to
its antioxidant properties
Pulmonary fibrosis, leucocytosis (42)
AC, Antiblastic chemotherapy; ADM, Doxorubicin; ALT, Alanine aminotransferase; BTZ, Bortezomib; CTX, Cyclophosphamide; CYP, Cytochrome P450; DAS, Dasatinib; DDP, Cisplatin;
ERL, Erlotinib; 5-FU, Fluorouracil; IA, Aromatase inhibitors; IMT, Imatinib; MTX, Methotrexate; NA, Not available; ND, Not documented; P-gp, P-glycoprotein; SOR, Sorafenib; TAM,
Tamoxifen; TXL, Paclitaxel; TXT, Docetaxel; VALK, Vinca alkaloids; VBL, Vinblastine; VCR, Vincristine; VP16, Etoposide.
Source: http://reference.medscape.com/drug-interactionchecker and Memorial Sloan Kettering Cancer Center: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/
ginseng-asian#references-24.
*Herbal mixture patented as a cancer therapy by Rene Caisse in 1920 in Canada.
◦Grifula frondosa (maitake), Lentinula edodes (shiitake), Ganoderma lucidum (reishi), etc.
§Somatostatin, Bromocriptine, Fluvoxamine, Melatonin.
∧Gastrointestinal complaints: diarrhea, vomiting, and nausea.
addressing the physicians’ point of view are now beginning to be
published. Since the attitudes toward CAM of Italian physicians
who treat patients with chronic disorders, including cancer, have
never been surveyed, we set out to investigate the personal and
professional characteristics and CAM attitudes, knowledge, and
use in a sample of physicians who predominantly treat this type
of patients.
MATERIALS AND METHODS
Participants
A nationwide cross-sectional descriptive questionnaire survey
was undertaken to collect data on CAM attitudes, knowledge
and use by physicians. Letters of invitation were sent to 20
institutions, which included: research hospitals, universities
and general hospitals, and 11 agreed to participate to the
survey. Physicians were invited to complete the questionnaire
by the researchers involved in the study (the chief of their
department/the chief medical officer). The study was conducted
in accordance with the 1964 Helsinki Declaration.
Participants were grouped into four specialty
groups: (G1) “Oncology/Hematology/Pain management
/Radiotherapy/Anaesthesiology” (40.4%); (G2) “Internal
medicine/Geriatric medicine/Infectious diseases” (25.3%); (G3)
“Surgical specialties” (15.1%); and (G4) Nuclear medicine/No
specialty/Other” (19.2%).
Questionnaire
A 41-item questionnaire was developed by two of the authors
(M.B. and A.C.) based on literature data (47) and divided into
3 sections. The first section collected personal and professional
data, including participant gender, age, education, medical
specialty, years of experience, type of institution and place of
work in Italy (North, Center, South and Islands). The second
section focused on CAM and asked questions on participants’
knowledge of it; their view of its ability to be used with CM;
whether they suggest CAM to patients or discuss it with them;
whether and how it could be used in their patients, their trust
in CM, and their personal use of CAM. The third section asked
which CAM interventions were known to the participant; to
which patients they would suggest CAM, the role they thought
it could have, and which effects they have actually observed. In
line with the literature (47), the commonly prescribed medical
therapies such as support therapy (e.g., iron, vitamin D, calcium
supplements) were not considered as CAM and are not included
in the analysis.
Statistical Analysis
All questionnaires were coded and checked. Missing data
and ambiguous responses were excluded from the analysis.
Participant information was summarized in descriptive tables.
Differences in participant characteristics and knowledge of CAM
were analyzed by the chi-square test or Fisher’s exact test, as
appropriate. The level of significance was set at p < 0.05.
Analyses were performed with IBM SPSS Statistics 25.0 (49).
The variables showing significant differences were entered into
a logistic regression model to test the relationships between
them (as independent variables) and the four specialty groups,
to gain insight into participants’ attitudes to CAM. Odds ratios
(ORs) and 95% confidence intervals (CIs) were computed
to assess participants’ attitudes using G1 physicians as the
reference category.
RESULTS
A total number of 438 participants responded, yielding an
adjusted response rate of 82% (534 physicians were invited and
96 incomplete questionnaires were excluded). Participants were
equally distributed among men and women and their median
age was 53 years (range, 30–67). As regards education, 55.7%
had a specialization, and only 5% had a Ph.D. degree; the
most common specialty areas were G1 (40.4%), G2 (25.3%),
G3 (15.1%), and G4 (19.2%); most participants (60.7%) worked
in institutions in Southern Italy and were involved in research
activity (54%) (Table 2).
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TABLE 2 | Personal and professional data of participants.
No. (%)
438 100.0
Gender
Male 220 50.2
Female 218 49.8
Age
<40 years 189 43.2
40–65 years 239 54.6
65 years 9 2.1
Missing 1 0.2
Education
Medical degree 112 25.6
Medical degree + specialization 224 55.7
Medical degree + specialization + Ph.D. 22 5
Master’s degree 12 2.7
Other 48 11
Specialty group
G1 177 40.4
G2 111 25.3
G3 66 15.1
G4 84 19.2
Years of practice
<5 years 118 26.9
5–10 years 70 16.0
> 10 years 209 47.7
Missing 41 9.4
Institution
Research hospital 134 30.6
University 194 44.3
General hospital 110 25.1
Institution location in Italy
North 125 28.5
Center 47 10.7
South and Islands 266 60.7
G1: Oncology, Hematology, Pain management, Radiotherapy, Anaesthesiology.
G2: Internal medicine, Geriatric medicine, Infectious diseases.
G3: Surgical; G4: Nuclear medicine, No specialization, Other.
Slightly more than half (50.9%) knew the meaning of the
CAM acronym; most (78.6%) knew about “alternative and
complementary medicine,” and most (41.8%) thought that CAM
could have a role in CM (Table 3).
The statistical comparisons based on specialty group are
reported in Table 4. G1 physicians were more likely to work
in Northern Italy (34.5%) in a research hospital (42.4%) and
were more interested in CAM than the other groups (“Do
you know what CAM stands for?” yes, 57.6%; “Have you ever
heard about alternative and complementary medicine?” yes, 88%;
“Should patients be treated exclusively with CM?” no, 52%). The
distribution of physicians involved in research activity and their
interest in CAM are reported in Table 5.
CAM knowledge and communication with patients were
analyzed by multivariate logistic regression (Table 6). G1
physicians were significantly associated with CAM knowledge
TABLE 3 | Key questions.
No. (%)
438 100.0
Are you involved in research activity?
Yes 240 54.8
No 198 45.2
Do you know what CAM stands for?
Yes 223 50.9
No 215 49.1
Have you ever heard about alternative and
complementary medicine?
Yes 342 78.6
No 93 21.4
Should patients be treated exclusively with
CM?
Yes 159 36.3
No 194 44.3
I don’t know 85 19.4
Do you suggest CAM to your patients?
Yes 241 55
No 197 45
Do you discuss CAM use with them?
Yes 193 44.1
No 212 48.4
I don’t know 33 7.5
Could CAM have a role in CM?
Yes 183 41.8
No 100 22.8
I don’t know 155 35.4
Have you seen therapeutic effects of
CAM?
Yes 203 46.3
No 180 41.1
I don’t know 55 12.6
Yes
Psychophysical well-being 95 46.8
Attenuation of treatment side-effects 53 26.1
Improved response rate 11 5.4
Response 1+2 18 8.9
Response 1+3 13 6.4
Response 1+2+3 13 6.4
Personal use of CAM
Yes 112 27.7
No 292 72.3
(p < 0.0001) and with awareness of the difference between
complementary and alternative medicine (p = 0.01). The lack
of an association between G1 physicians and CAM suggestion
and prescription to their patients explains their poor propensity
for CAM interventions (p = 0.4 and 0.09, respectively). About
half of participants stated that they do not discuss CAM with
their patients.
The CAM interventions best known to our sample of
physicians (Figure 1) were acupuncture (60.7%), Aloe vera
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TABLE 4 | Physicians’ characteristics and their CAM knowledge according to their specialty.
Characteristics Specialty group
G1 Oncology, hematology,
pain management,
radiotherapy,
anaesthesiology
G2 Internal medicine,
geriatric medicine, infectious
diseases
G3 Surgical specialties G4 Nuclear medicine, no
specialization, other
No. (%) No. (%) p-value 1* No. (%) p-value 2* No. (%) p-value 3*
Gender 0.5 0.06 0.2
Female 88 (49.7) 59 (53.2) 24 (36.4) 49 (58.3)
Male 89 (50.3) 52 (46.8) 42 (63.6) 35 (41.7)
Age 0.001 0.6 0.6
< 40 years 66 (37.3) 66 (59.5) 29 (43.9) 28 (33.3)
40–65 years 107 (60.5) 43 (38.7) 35 (53) 55 (65.5)
65 years 4 (2.3) 2 (1.8) 2 (3) 1 (1.2)
Time elapsed since
specialization
<0.0001 0.1 0.5
< 5 years 39 (23.2) 51 (52.6) 8 (16.7) 20 (23.8)
5–10 years 36 (21.4) 5 (5.2) 6 (12.5) 23 (27.4)
≥ 10 years 93 (55.4) 41 (42.3) 34 (70.8) 41 (48.8)
Workplace location <0.0001 0.8 0.8
Northern Italy 61 (34.5) 17 (15.3) 21 (31.8) 26 (31)
Central Italy 20 (11.3) 9 (8.1) 7 (10.6) 11 (13.1)
Southern Italy 96 (54.2) 85 (76.6) 38 (57.6) 47 (56)
Institution <0.0001 <0.0001 0.004
Research hospital 75 (42.4) 8 (7.2) 15 (22.7) 36 (42.9)
University 47 (26.6) 72 (64.9) 39 (59.1) 36 (42.9)
General hospital 55 (31.1) 31 (27.9) 12 (18.2) 12 (14.3)
Are you involved in research
activity?
0.001 0.9 0.9
Yes 106 (59.9) 44 (39.6) 40 (60.6) 50 (59.5)
No 71 (40.1) 67 (60.4) 26 (39.4) 34 (40.5)
Do you know what CAM stands
for?
0.01 0.1 0.3
Yes 102 (57.6) 47 (42.3) 31 (47) 43 (51.2)
No 75 (42.4) 64 (57.7) 35 (53) 41 (48.8)
Have you ever heard about
alternative and complementary
medicine?
<0.0001 0.03 0.001
Yes 154 (88) 78 (70.3) 50 (76.9) 60 (71.4)
No 21 (12) 33 (29.7) 15 (23.1) 24 (28.6)
Should patients be treated
exclusively with CM?
0.1 0.06 0.02
Yes 58 (32.8) 41 (36.9) 32 (48.5) 28 (33.3)
No 92 (52) 46 (41.4) 24 (36.4) 32 (38.1)
I don’t know 27 (15.3) 24 (21.6) 10 (15.2) 24 (28.6)
Do you suggest CAM to your
patients?
0.2 0.3 0.6
Yes 102 (57.6) 55 (49.5) 33 (50) 51 (60.7)
No 75 (42.4) 56 (50.5) 33 (50) 33 (39.3)
Do you discuss CAM use with
your patients?
0.2 0.1 0.1
Yes 87 (49.2) 51 (45.9) 25 (37.9) 30 (35.7)
No 74 (41.8) 55 (49.5) 37 (56.1) 46 (54.8)
I don’t know 16 (9) 5 (4.5) 4 (6.1) 8 (9.5)
(Continued)
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TABLE 4 | Continued
Characteristics Specialty group
G1 Oncology, hematology,
pain management,
radiotherapy,
anaesthesiology
G2 Internal medicine,
geriatric medicine, infectious
diseases
G3 Surgical specialties G4 Nuclear medicine, no
specialization, other
No. (%) No. (%) p-value 1* No. (%) p-value 2* No. (%) p-value 3*
Could CAM have a role in CM? 0.005 0.3 0.09
Yes 86 (48.6) 37 (33.3) 26 (39.4) 34 (40.5)
No 33 (18.6) 38 (34.2) 18 (27.3) 11 (13.1)
I don’t know 58 (32.8) 36 (32.4) 22 (33.3) 39 (46.4)
CAM could play a role as: 0.9 0.4 0.3
Alternative medicine 11 (6.2) 10 (9) 2 (3) 4 (4.8)
Complementary therapy 88 (49.7) 55 (49.5) 34 (51.5) 42 (50)
Integrated medicine 40 (22.6) 26 (23.4) 18 (27.3) 23 (27.4)
I don’t know 38 (21.5) 20 (18) 12 (18.2) 15 (17.9)
CAM use by participants 0.7 0.6 0.7
Yes 43 (25.9) 27 (25.5) 19 (31.7) 23 (31.9)
No 123 (74.1) 79 (74.5) 41 (68.3) 49 (68.1)
*P1; P2; P3: p-values of Pearson’s chi-square test comparing G1 physicians with G2 physicians (P1); with G2 physicians (P2); and with G3 physicians (P3).
Bold values indicate statistically significant p-value.
(57.1%), and high-dose vitamin C (40.6%); the least known
were Hamer’s method (12%) and Rophalurus junceus (poison
of the blue scorpion, marketed as “Escozul”) (8.3%). We
decided to exclude from this list the medical therapies that are
usually prescribed as support therapy (iron, vitamin D, and
calcium supplements).
The patients to whom participants would recommend CAM
therapies (Figure 2) are those with cancer and chronic disease
(similar percentages). A significant association was found for
none of the specialty groups.
As regards the possible use of CAM (Figure 3), G1 physicians
would not recommend their cancer patients to treat their disease
with CAM alone (10%) but would recommend it as a support
treatment (55%) during AC, whereas G4 physicians would
recommend CAM as a ACT (60%). Most (33%) G2 and G3
physicians consider CAM as useless and expensive.
DISCUSSION
In recent years the interest in CAM has mounted considerably
due to media influence and to internet marketing, besides
patients’ desire to gain greater control on their treatment. The
available data suggest that although 29–91% of chronic and
cancer patients use CAM remedies together with their treatment,
less than half of physicians, and especially of oncologists, discuss
them with their patients (4, 5, 7). CAM has largely been ignored
by physicians for at least 30 years and has only recently begun
to attract the attention of the scientific community and of
healthcare institutions.
This study surveyed the CAM knowledge, use, perception,
and attitudes of Italian physicians who predominantly treat
patients with chronic disease, including cancer. Although 44%
of participants believe that patients should be treated exclusively
with CM, most (59%) replied that they accept and prescribe
CAM interventions. The patients to whom they would prescribe
CAM are predominantly those with cancer (76%) or chronic
disease (74%) as well as terminally ill (49%) and elderly patients
(47%). Moreover, 45% (p< 0.005) of those surveyed believed that
CAM could have a role in CM as a complementary therapy in
a context of integrative medicine (IM), as also found by several
studies (20, 50–55). Indeed, IM models for cancer patients are
applied in hospital setting in several countries (56–59). The
analysis of physicians’ characteristics highlighted that 40% of
our sample are involved in treating cancer patients and work
at a university (44%) or a research hospital (31%). Awareness
of CAM was acknowledged by 60% of oncologists, by 42% of
internal medicine specialists and 45% of “other” specialists; their
different knowledge may be due to the widespread use of CAM
remedies by cancer patients. This 60% of oncologists constitutes
a significant improvement on the 48% described by Crocetti
et al. (47) in 1996 and reflects a much greater awareness and
knowledge of CAM, a greater attention to the problem and an
increased use of CAM in Italy. Participant age (40–65 years)
and years of practice (>10 years) were found to be significantly
associated with CAM knowledge (respectively, p < 0.001 and
p < 0.002); a similar finding has been reported in a recent
national survey of China’s oncologists (60). As expected, the
physicians with a more limited knowledge of CAM were less
likely to discuss it with patients, as also noted by other researchers
(61). A recent Norwegian study of cancer patients who use
complementary medicine suggests that poor communication
experiences with physicians may result in the adoption of
CAM interventions, and in some cases in postponement or
reduction of the conventional cancer treatment; in contrast,
positive communication experiences led to CAM use as a
supplement rather than an alternative to CM (62). Effective
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TABLE 5 | CAM knowledge in relation to participants’ involvement in
research activity.
Are you involved in
research activity?
p-value
Yes No
Do you know what CAM stands
for?
0.6
Yes 120 (50) 103 (52)
No 120 (50) 95 (48)
Have you ever heard about
alternative and complementary
medicine?
0.01
Yes 199 (82.9) 143 (73.3)
No 41 (17.1) 52 (26.7)
Are you aware of the difference
between complementary and
alternative medicine?
0.04
Yes 152 (63.6) 106 (53.8)
No 87 (36.4) 91 (46.2)
Do you suggest CAM to your
patients?
0.03
Yes 143 (59.6) 98 (49.5)
No 97 (40.4) 100 (50.5)
Could CAM have a role in CM? 0.02
Yes 109 (45.4) 74 (37.4)
No 43 (17.9) 57 (28.8)
I don’t know 88 (36.7) 67 (33.8)
Do you discuss CAM use with
your patients?
0.1
Yes 108 (45) 85 (42.9)
No 109 (45.4) 103 (52)
I don’t know 23 (9.6) 10 (5.1)
Specialty group 0.003
G1 106 (44.2) 71 (35.9)
G2 44 (18.3) 67 (33.8)
G3 40 (16.7) 26 (13.1)
G4 50 (20.8) 34 (17.2)
G1: Oncology, Hematology, Pain management, Radiotherapy, Anaesthesiology; G2:
Internal medicine, Geriatric medicine, Infectious diseases; G3: Surgical; G4: Nuclear
medicine, No specialization, Other.
Bold values indicate statistically significant p-value.
patient-physician communication may be critical for patient
satisfaction and compliance and for favorable outcomes. Patients’
negative attitudes toward CM have also been linked to possible
adverse reactions to treatment (62). The Norwegian study also
reported that patients who had been with the same general
practitioner (GP) for more than 2 years were less likely to visit
a complementary medicine provider than those with a shorter
relationship with their GP (12.5 vs. 15.5%, respectively) (62).
Notably, the lack of communication between physicians and
providers of complementary interventions is an additional risk
for patients who wish to combine what they perceive to be the
best of the two worlds.
Interestingly, a study of data from a Dutch health insurance
company (63) has found that the patients of GPs who had had
CAM training had lower mortality rates and cost less to the
TABLE 6 | Odds ratio (OR) and 95% confidence intervals (CIs) computed to
assess the attitudes toward CAM of G1 physicians (specialties: Oncology,
Hematology, Pain management, Radiotherapy, Anaesthesiology).
G1 vs.
G2, G3, G4
p-value
OR
†
95% CI
Do you know what CAM stands for?
Yes 1.52 (1.02–2.25) 0.004
No 1.00 (Reference
category)
Have you ever heard about alternative
and complementary medicine?
Yes 2.64 (1.54–4.52) <0.0001
No 1.00
Are you aware of the difference between
complementary and alternative
medicine?
Yes 1.77 (1.18–2.68) 0.006
No 1.00
Do you suggest CAM to your patients
Yes 1.16 (0.79–1.72) 0.4
No 1.00
Have you ever prescribed CAM to your
patients?
Yes 1.47 (0.93–2.32) 0.09
No 1.00
†
Logistic regression model adjusted for age, gender, area of origin and workplace.
Bold values indicate statistically significant p-value.
healthcare system due to shorter hospital stays and fewer drug
prescriptions. In addition, various studies indicate that better
educated patients with higher than average incomes are more
likely to choose CAM and are frequently supported in this
choice by their GPs (7, 64–66). Informing physicians about the
high prevalence of CAM use and the commonly used CAM
interventions has the potential to advance communication with
patients. Our survey found that half of physicians discuss the
role of CAM with their patients: these physicians are those
who are involved in research work, have more than 10 years of
specialization and belong to G1 group.
The need for improving physicians’ CAM knowledge and
communication with patients has also been highlighted in
recent studies by the Working Group Prevention and Integrative
Oncology of the German Cancer Society (54), the German society
for Palliative Medicine (67), other German institutions (68, 69)
and the national survey of China’s oncologists (60). The German
studies also indicate that some CAM practices (psycho-oncology,
sport, micronutrient supplements) are more popular in Germany
than in Italy.
Negative experiences related to physician-patient interactions
and CM outcomes can encourage cancer patients to use CAM
and to refuse or postpone CM (70).
In our survey, the physicians working at a university and/or
a research hospital knew CAM significantly better than those
who worked at a general hospital (p < 0.0001), and those who
were also involved in research work knew CAM better than
those who did no research (p < 0.003). Similar results are
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FIGURE 1 | Type of CAM interventions known to participants in relation to specialty group.
FIGURE 2 | Physicians answer to the question “To whom would you suggest using CAM?”.
reported in the national survey of Chinese oncologists: those
working in metropolitan areas and academic hospitals have a
greater knowledge of and a more favorable attitude toward
CAM (60). Interestingly, in our survey 60% of the physicians
involved in research would suggest CAM to patients, and 45%
of them discuss it with them; surprisingly, this is also the
proportion of physicians who do no research (p < 0.1). Our
survey demonstrated that the lack of communication about CAM
between physicians and patients is not necessarily related to
physicians’s knowledge of CAM. The CAM interventions best
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FIGURE 3 | Participants’ perception of the value of CAM interventions in relation to their specialty group.
known to participants were acupuncture (60.7%), Aloe vera
(57.1%), high-dosage vitamin C (40.6%), and yoga (36.1%),
whereas the least known was Escozul (8.3%). Surgeons were the
physicians with the most limited CAM knowledge. All physicians
stated they would prescribe CAM chiefly to patients with cancer
and/or chronic disease; 33% of internal medicine physicians feel
that CAM is useless and expensive, 50% of oncologists think that
CAM remedies could be used as supplements, and 47% of them
consider CAM useful as support in chronic treatments. Notably,
most (55%) G1 physicians view CAM as a support treatment
during ACT and only 10% believe that it can be used as an ACT.
Interestingly, 30 and 60% of G2 and G4 physicians, respectively,
believe that CAM can have a role as an ACT. Such widely
different views could be related to lack of CAM training in the
medical degree course. Similar to our oncologists, the national
survey found that China’s oncologists accept CAM (44.9% of
participants) to manage the most common symptoms related
to cancer treatment such as lack of appetite, fatigue and sleep
disorder (60), i.e., as support treatment. Moreover, 22% of G1
and 33% of G2 and G3 physicians consider CAM expensive
and useless. To improve CAM knowledge, most U.S. medical
schools (64%) are offering alternative medicine courses (69, 71).
Moreover, a recent study has reported that 95% of students in an
Arabic medical school were satisfied with a course on integrative
and prophetic medicine (72). These data indicate an increasing
need for greater insight into CAM interventions, mostly for use
with CM.
The two chief limitations of the study are the size of
the sample and the fact that an interest in CAM may have
enhanced respondents’ willingness to participate. However, this
the first survey involving a large number of physicians of several
specialties, all of whom are involved in treating patients with
chronic conditions, including cancer. Moreover, analysis of their
responses, to highlight different approaches to CAM, enabled
extensive dissection of the data, since participants were grouped
into specialty groups as well as by their involvement in research
work and the type and geographical site of their institution.
In conclusion, our survey provides up to date information
about physician’s knowledge of CAM and their attitudes to
it. The CAM awareness of Italian physicians has considerably
improved since the late 1990’s, when a similar questionnaire
was distributed, and their attitudes have changed accordingly.
Although it is difficult to assess their CAM knowledge, attitudes
and practice patterns and their true prevalence, we believe that
this survey provides new and topical information. Since in Italy
the question is increasingly being discussed by the medical and
the lay community alike, this study provides a long overdue
update on a highly topical issue.
PERSPECTIVES
The lack of CAM knowledge by physicians and their limited
communication with patients have negative consequences on and
implications for clinical management and outcomes. Notably,
it has been demonstrated that the use of CAM instead of
CM was associated with worse five-year survival in cancer
patients (73). The use of CAM by cancer patients is therefore
an outstanding issue that warrants greater attention by the
scientific community and physicians. Critically, its unguided use
by patients with chronic disease and/or cancer has important
implications for healthcare services and care providers as well
as for the patients themselves. Assessing the soundness of
CAM information sources and improving communication with
physicians on this topic is crucial to enhance or preserve patient
health and to strengthen the therapeutic relationship and patient
compliance. We believe that physicians should expand their
knowledge of CAM interventions, beneficial effects and potential
interactions and toxicity. Indeed, an earlier pilot study (74)
has identified 47 different potential interactions among 136
herb-drug combinations whereas a more recent investigation
has found that 37.2% of patients were at risk of interaction
between CM and CAM interventions (75). This risk can be
reduced by improving physician-patient communication, as
shown by several studies (50–55, 76, 77), as well as by the
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adoption of an integrative medicine model. It would be useful
to run clinical trials on some interventions, like mushrooms,
mistletoe, ozone, and high-dose vitamin C, for which there
is some scientific evidence (78–87). It is essential to find
an evidence base for CAM therapies using suitable, sensitive
approaches. Discussion of CAM interventions and guidance
on potential benefits and toxicities is a task that physicians
should urgently undertake. Extensive research is required to
assess actual CAM use and dosage in patients receiving
different treatments and to work toward achieving an integrated
model of healthcare provision, which should also inform
EU legislation.
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